AN2 Therapeutics, Inc.
ANTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001880438
In the last 90 days, AN2 Therapeutics, Inc. insiders filed 1 open-market purchase and 5 sales; 66 institutions reported holding it in 13F filings for Q2 2026, worth $119.0M in total; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in AN2 Therapeutics, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- +18 vs. Q4 2021
- Shares held
- 8.95M
- +8.95M vs. Q4 2021
- Total value
- $134.1M
- +$134.1M vs. Q4 2021
- New holders
- 18
- 0 more added
- Sold out
- 0
- 0 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ANTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 66 | $119.0M |
| Q1 2026 | 52 | $74.8M |
| Q4 2025 | 38 | $9.88M |
| Q3 2025 | 36 | $10.5M |
| Q2 2025 | 37 | $8.78M |
| Q1 2025 | 38 | $19.5M |
| Q4 2024 | 38 | $20.1M |
| Q3 2024 | 31 | $14.5M |
| Q2 2024 | 45 | $41.7M |
| Q1 2024 | 54 | $60.9M |
| Q4 2023 | 51 | $417.9M |
| Q3 2023 | 37 | $320.3M |
| Q2 2023 | 31 | $99.9M |
| Q1 2023 | 38 | $94.8M |
| Q4 2022 | 36 | $92.9M |
| Q3 2022 | 38 | $165.1M |
| Q2 2022 | 36 | $72.4M |
| Q1 2022 | 18 | $134.1M |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding AN2 Therapeutics, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 3,666,663 | $55.3M | 1.21% | +3,666,663 | New |
| BVF Inc | 1,616,665 | $24.4M | 0.97% | +1,616,665 | New |
| Citadel Advisors LLC | 1,419,851 | $20.6M | 0.02% | +1,419,851 | New |
| Avidity Partners Management LP | 688,330 | $10.4M | 0.23% | +688,330 | New |
| Deerfield Management Company, L.P. (Series C) | 584,136 | $8.80M | 0.20% | +584,136 | New |
| Monashee Investment Management LLC | 433,330 | $6.53M | 1.89% | +433,330 | New |
| Woodline Partners LP | 150,000 | $2.26M | 0.04% | +150,000 | New |
| Alyeska Investment Group, L.P. | 125,000 | $1.88M | 0.02% | +125,000 | New |
| Vanguard Group Inc | 74,733 | $1.13M | 0.00% | +74,733 | New |
| Millennium Management LLC | 74,238 | $1.12M | 0.00% | +74,238 | New |
| Cowen and Company, LLC | 60,278 | $908.0K | 0.09% | +60,278 | New |
| Goldman Sachs Group Inc | 19,497 | $294.0K | 0.00% | +19,497 | New |
| Barclays PLC | 18,220 | $275.0K | 0.00% | +18,220 | New |
| Wellington Management Group LLP | 16,600 | $250.0K | 0.00% | +16,600 | New |
| Anson Funds Management LP | 2,500 | $38.0K | 0.01% | +2,500 | New |
| UBS Group AG | 1,158 | $17.0K | 0.00% | +1,158 | New |
| Morgan Stanley | 885 | $14.0K | 0.00% | +885 | New |
| Tower Research Capital LLC (TRC) | 653 | $10.0K | 0.00% | +653 | New |